NCT03308799View on ClinicalTrials.gov

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

PHASE3CompletedINTERVENTIONAL
Enrollment

794

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

June 8, 2018

Study Completion Date

June 8, 2018

Conditions
Psoriasis Vulgaris
Interventions
DRUG

MC2-01 cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

DRUG

Cal/BDP combination

calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

DRUG

Cream vehicle

Vehicle Cream

Trial Locations (3)

48202

Henry Ford Hospital, Detroit

55432

Minnesota Clinical Study Center, Fridley

99202

Richard Herdener, MD, Spokane

Sponsors

Lead Sponsor

MC2 Therapeutics
All Listed Sponsors
lead

MC2 Therapeutics

INDUSTRY